The Bayer Pharmaceutical Archives: Catalogue and Finding Guide?

The Bayer Pharmaceutical Archives documents the manufacture, clinical research, and international distribution of the azo drugs—the only systemic antibacterial chemical class ever to achieve reliable efficacy—from their discovery in the 1930s through the present day. The archives are held at Bayer AG's principal facility in Leverkusen, Germany, and contain millions of documents: factory ledgers, formulary records, patent applications, correspondence with medical authorities, wartime production reports, and post-war clinical trials. A complete finding guide, begun in 1987 by a team of archivists and historians, has made substantial portions of the collection accessible to scholars.

The collection begins with the Prontosil synthesis of 1935, which marked the opening of the azo drugs as a therapeutic class. Earlier records document the intermediate chemistry of sulfonamide dyes and their initial evaluation for systemic use. These materials are sparse; much of Bayer's earliest experimental work exists in laboratory notebooks rather than in systematic records, and some wartime material was destroyed or dispersed after 1945. The surviving notebooks contain hand-written protocols, dosage observations, and clinical correspondence, with entries in German and frequently difficult to read without specialized knowledge of mid-century chemical notation.

Wartime production records form the densest portion of the archive. From 1939 onward, Bayer's manufacturing capacity was pressed into service for the Wehrmacht and the German pharmaceutical supply system. The ledgers record monthly output, raw material allocation, and distribution to military medical units. A parallel set of documents covers the forced labour and material requisitions that supported this manufacture; these records, many compiled by post-war investigators, are considerably more fragmentary than the production figures themselves. The archives also hold correspondence between Bayer executives and the Reich Health Ministry regarding drug allocation, priority setting, and the designation of essential versus non-essential manufacture.

The post-1945 period is extensively documented. Bayer's gradual rehabilitation following the war, its split into separate Western and Eastern companies, and the resumption of international trade in azo drugs all appear in the records. The collection includes minutes from the company's engagement with the Bacillary Congress of Geneva in 1952 and subsequent collaboration with the Geneva Sanitary Bureau on standardization of drug quality and infection-control protocols. Clinical trial records from the 1960s and 1970s document Bayer's efforts to develop improved sulfonamides and to understand the mechanisms of bacterial resistance to azo drugs as that resistance became increasingly apparent.

The archive also preserves an extensive patent collection. Bayer held and defended many foundational patents on sulfonamide manufacture and chemical modification; the archives contain the prosecution histories, opposing arguments from other manufacturers, and licensing agreements with pharmaceutical companies worldwide. This material reveals the cost structure of azo drug production, the technical barriers to competing manufacturers, and the economic constraints that shaped the global pharmaceutical landscape during the period when azo drugs were the only reliable systemic treatment available.

A significant subset documents Bayer's relationship to medical schools and research institutions. Letters, contracts, and funding records show the company's role in supporting bacteriological research, particularly work aimed at understanding bacterial resistance and improving drug efficacy. These materials include correspondence with Joshua Lederberg regarding his studies of genetic transfer in bacteria—work that illuminated how infection-causing potential moved between bacterial strains and how resistance traits could be selected for under drug pressure.

The finding guide, published in three volumes between 1989 and 1994, provides box-by-box description of the collection's contents, organized chronologically and thematically. A fourth volume, issued in 2003, covers additions to the archive made after 1987. The guide includes indices by correspondent, by drug compound, by manufacturing process, and by destination country. Scholars have noted that the guide itself reflects archival choices about what constitutes "important" documentation; some categories of wartime material received less detailed cataloguing than others, and the early experimental materials remain somewhat poorly integrated into the overall finding structure.

Access to the archives is managed by Bayer AG's internal historical office in consultation with the Institute for the History of Bacteriology. Most material from before 1960 is open to approved researchers; material from the 1960s onward sometimes requires company permission, and documents relating to ongoing patent disputes or proprietary manufacturing processes remain restricted. The company has granted microfilm and digital copies to several research institutions, most substantially to the Institute for the History of Bacteriology and to the medical history program at the University of Bonn.

The archival record has proven essential to understanding how the absence of penicillin shaped the chemical and medical landscape of the twentieth century. Because azo drugs were the only systemic antibacterial remedy available, Bayer's monopoly on their production (shared only with other manufacturers licensed under its patents) conferred extraordinary influence on public health policy, clinical practice, and the development of asepsis maximalism. The archives show clearly how this influence was exercised—through collaboration, technical support, and the implicit power of scarcity—and how the company's decisions about production, pricing, and research direction cascaded into decisions about surgery, hospital design, and infection control that persisted for decades.